MedPath

BIOMARIN PHARMACEUTICAL AUSTRALIA PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

12

TGA:12

Drug Approvals

VOXZOGO vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe (376617)

Product Name
VOXZOGO vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe
Approval Date
Jul 6, 2022
TGA

VOXZOGO vosoritide 1.2 mg powder for injection vial and diluent pre-filled syringe (376618)

Product Name
VOXZOGO vosoritide 1.2 mg powder for injection vial and diluent pre-filled syringe
Approval Date
Jul 6, 2022
TGA

VOXZOGO vosoritide 0.4 mg powder for injection vial and diluent pre-filled syringe (376616)

Product Name
VOXZOGO vosoritide 0.4 mg powder for injection vial and diluent pre-filled syringe
Approval Date
Jul 6, 2022
TGA

PALYNZIQ pegvaliase 10 mg/0.5 mL solution for injection pre-filled syringe (341754)

Product Name
PALYNZIQ pegvaliase 10 mg/0.5 mL solution for injection pre-filled syringe
Approval Date
Jul 14, 2021
TGA

PALYNZIQ pegvaliase 2.5 mg/0.5 mL solution for injection pre-filled syringe (341753)

Product Name
PALYNZIQ pegvaliase 2.5 mg/0.5 mL solution for injection pre-filled syringe
Approval Date
Jul 14, 2021
TGA

PALYNZIQ pegvaliase 20 mg/mL solution for injection pre-filled syringe (341752)

Product Name
PALYNZIQ pegvaliase 20 mg/mL solution for injection pre-filled syringe
Approval Date
Jul 14, 2021
TGA

KUVAN sapropterin dihydrochloride 500 mg oral powder sachet (297734)

Product Name
KUVAN sapropterin dihydrochloride 500 mg oral powder sachet
Approval Date
Dec 13, 2018
TGA

KUVAN sapropterin dihydrochloride 100 mg oral powder sachet (297728)

Product Name
KUVAN sapropterin dihydrochloride 100 mg oral powder sachet
Approval Date
Dec 13, 2018
TGA

BRINEURA cerliponase alfa (rch) 150 mg/5 mL solution for injection vial with flushing solution vial (298672)

Product Name
BRINEURA cerliponase alfa (rch) 150 mg/5 mL solution for injection vial with flushing solution vial
Approval Date
Aug 28, 2018
TGA

VIMIZIM elosulfase alfa (rch) 1 mg/mL concentrated solution for injection vial (215523)

Product Name
VIMIZIM elosulfase alfa (rch) 1 mg/mL concentrated solution for injection vial
Approval Date
Dec 9, 2014
TGA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.